GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Endocyte Inc (NAS:ECYT) » Definitions » Graham Number

Endocyte (Endocyte) Graham Number : $N/A (As of Sep. 2018)


View and export this data going back to 2011. Start your Free Trial

What is Endocyte Graham Number?

Graham Number is a figure that measures a stock's fundamental value by taking into account the company's earnings per share and book value per share. The Graham number is the upper bound of the price range that a defensive investor should pay for the stock. According to the theory, any stock price below the Graham number is considered undervalued, and thus worth investing in.

As of today (2024-05-07), the stock price of Endocyte is $23.99. Endocyte's graham number for the quarter that ended in Sep. 2018 was $N/A. Therefore, Endocyte's Price to Graham Number ratio for today is N/A.

The historical rank and industry rank for Endocyte's Graham Number or its related term are showing as below:

ECYT's Price-to-Graham-Number is not ranked *
in the Biotechnology industry.
Industry Median: 2.165
* Ranked among companies with meaningful Price-to-Graham-Number only.

Graham Number is a combination of asset valuation and earnings power valuation. It is a very conservative way of valuing a stock.


Endocyte Graham Number Historical Data

The historical data trend for Endocyte's Graham Number can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Endocyte Graham Number Chart

Endocyte Annual Data
Trend Dec08 Dec09 Dec10 Dec11 Dec12 Dec13 Dec14 Dec15 Dec16 Dec17
Graham Number
Get a 7-Day Free Trial Premium Member Only Premium Member Only - 3.79 - - -

Endocyte Quarterly Data
Dec13 Mar14 Jun14 Sep14 Dec14 Mar15 Jun15 Sep15 Dec15 Mar16 Jun16 Sep16 Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18
Graham Number Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Endocyte's Graham Number

For the Biotechnology subindustry, Endocyte's Price-to-Graham-Number, along with its competitors' market caps and Price-to-Graham-Number data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Endocyte's Price-to-Graham-Number Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Endocyte's Price-to-Graham-Number distribution charts can be found below:

* The bar in red indicates where Endocyte's Price-to-Graham-Number falls into.



Endocyte Graham Number Calculation

Graham Number is a concept based on Ben Graham's conservative valuation of companies.

Endocyte's Graham Number for the fiscal year that ended in Dec. 2017 is calculated as

Graham Number
=sqrt of (22.5* Tangible Book per Share *EPS without NRI)
=sqrt of (22.5*1.981*-1.25)
=N/A

Endocyte's Graham Number for the quarter that ended in Sep. 2018 is calculated as

Graham Number
=sqrt of (22.5*Tangible Book per Share*EPS without NRI (TTM))
=sqrt of (22.5*4.269*-0.66)
=N/A

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Endocyte  (NAS:ECYT) Graham Number Explanation

Ben Graham actually did not publish a formula like this. But he wrote in The Intelligent Investor (1948 version) regarding to the criteria for purchases:

Current price should not be more than 15 times average earnings of the past three years.

Current price should not be more than 1.5 times the book value last reported. However, a multiplier of earnings below 15 could justify a correspondingly higher multiplier of assets. As a rule of thumb we suggest that the product of the multiplier times the ratio of price to book value should not exceed 22.5. (This figure corresponds to 15 times earnings and 1.5 times book value. It would admit an issue selling at only 9 times earnings and 2.5 times asset value, etc.)

Unlike valuation methods such as DCF or Discounted Earnings, the Graham number does not take growth into the valuation. Unlike the valuation methods based on book value alone, it takes into account the earnings power. Therefore, the Graham Number is a combination of asset valuation and earnings power valuation.

In general, the Graham number is a very conservative way of valuing a stock. It cannot be applied to companies with negative book values.

Endocyte's Price to Graham number Ratio for today is calculated as

Price to Graham number=Share Price (Today)/Graham number (Q: Sep. 2018 )
=23.99/N/A
=N/A

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Please keep these in mind:

1. Graham Number does not take growth into account. Therefore it underestimates the values of the companies that have good earnings growth. We feel that if the earnings per share grows more than 10% a year, Graham Number underestimates the value.
2. Graham Number punishes the companies that have temporarily low earnings. Therefore, an average of earnings makes more sense in the calculation of Graham Number.
3. Graham Numbers underestimates companies that are light with book.


Endocyte Graham Number Related Terms

Thank you for viewing the detailed overview of Endocyte's Graham Number provided by GuruFocus.com. Please click on the following links to see related term pages.


Endocyte (Endocyte) Business Description

Traded in Other Exchanges
N/A
Address
Endocyte Inc is a biopharmaceutical company developing targeted therapies for the treatment of cancer and inflammatory diseases using precision medicine. Precision medicine is a medical discipline seeking to treat diseased cells with minimal impact on healthy cells. The company uses its proprietary technology to create novel small-molecule drug conjugates and companion imaging agents. The company's therapeutic areas are non-small cell lung, breast, colorectal, kidney, endometrial, prostate, and ovarian cancers; solid tumors; polycystic kidney disease; and inflammation.
Executives
Patrick Machado director 201 SPEAR STREET, 3RD FLOOR, SAN FRANCISCO CA 94107
John C Aplin director ONE AMERICAN SQUARE STE 2850, INDIANAPOLIS IN 46282
David R. Mcavoy officer: General Counsel C/O ENDOCYTE, INC., 3000 KENT AVENUE, SUITE A1-100, WEST LAFAYETTE IN 47906
Alison A. Armour officer: Chief Medical Officer C/O ENDOCYTE, INC., 3000 KENT AVENUE, SUITE A1-100, WEST LAFAYETTE IN 47906
Dawn Svoronos director C/O MEDIVATION, INC., 525 MARKET ST., 36TH FLOOR, SAN FRANCISCO CA 94105
Marc D Kozin director
Michael T. Andriole officer: Chief Financial Officer C/O ENDOCYTE, INC., 3000 KENT AVENUE, SUITE A1-100, WEST LAFAYETTE IN 47906
Lesley Russell director 41 MOORES RD., FRAZER PA 19355
Beth Taylor officer: VP Finance & Chief Acctg Off 3000 KENT AVENUE, SUITE A1-100, WEST LAFAYETTE IN 47906
Michael A. Sherman director, officer: President and CEO 3000 KENT AVE STE A1-100, WEST LAFAYETTE IN 47906
Fred A Middleton director 400 SOUTH EL CAMINO REAL STE 1200, SAN MATEO CA 94402-1708
Peter D Meldrum director 320 WAKARA WAY, SALT LAKE CITY UT 84108
Ann Hanham director ONE EMBRACADERO CTR, STE 2700, SAN FRANCISCO CA 94111
Chandra D Lovejoy officer: VP of Regulatory Affairs C/O PRONAI THERAPEUTICS, INC. 2150 - 885 WEST GEORGIA ST VANCOUVER A1 V6C 3E8
David D. Meek officer: Chief Commercial Officer 3000 KENT AVENUE; SUITE A1-100, WEST LAFAYETTE IN 47906

Endocyte (Endocyte) Headlines

From GuruFocus

Endocyte becomes first Purdue startup to reach $1.5B in value

By Marketwired Marketwired 10-03-2018

UPDATE - Endocyte Announces Presentations at the CAR-TCR Summit 2018

By GlobeNewswire GlobeNewswire 08-28-2018

Endocyte Announces Pricing of Public Offering of Common Stock

By GlobeNewswire GlobeNewswire 09-12-2018